90 related articles for article (PubMed ID: 23217660)
1. Relationships between pharmacotherapy-induced metabolic changes and improved psychopathology in schizophrenia: data from a mirtazapine and first-generation antipsychotics combination trial.
Terevnikov V; Stenberg JH; Tiihonen J; Chukhin E; Joffe M; Burkin M; Joffe G
Int J Neuropsychopharmacol; 2013 Aug; 16(7):1661-6. PubMed ID: 23217660
[TBL] [Abstract][Full Text] [Related]
2. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial.
Joffe G; Terevnikov V; Joffe M; Stenberg JH; Burkin M; Tiihonen J
Schizophr Res; 2009 Mar; 108(1-3):245-51. PubMed ID: 19144501
[TBL] [Abstract][Full Text] [Related]
3. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.
Berk M; Gama CS; Sundram S; Hustig H; Koopowitz L; D'Souza R; Malloy H; Rowland C; Monkhouse A; Monkhouse A; Bole F; Sathiyamoorthy S; Piskulic D; Dodd S
Hum Psychopharmacol; 2009 Apr; 24(3):233-8. PubMed ID: 19330802
[TBL] [Abstract][Full Text] [Related]
4. More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial.
Terevnikov V; Stenberg JH; Joffe M; Tiihonen J; Burkin M; Tchoukhine E; Joffe G
Hum Psychopharmacol; 2010 Aug; 25(6):431-8. PubMed ID: 20737516
[TBL] [Abstract][Full Text] [Related]
5. Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase.
Terevnikov V; Stenberg JH; Tiihonen J; Joffe M; Burkin M; Tchoukhine E; Joffe G
Hum Psychopharmacol; 2011 Apr; 26(3):188-93. PubMed ID: 21469215
[TBL] [Abstract][Full Text] [Related]
6. The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial.
Abbasi SH; Behpournia H; Ghoreshi A; Salehi B; Raznahan M; Rezazadeh SA; Rezaei F; Akhondzadeh S
Schizophr Res; 2010 Feb; 116(2-3):101-6. PubMed ID: 19959338
[TBL] [Abstract][Full Text] [Related]
7. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia.
Stenberg JH; Terevnikov V; Joffe M; Tiihonen J; Tchoukhine E; Burkin M; Joffe G
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1080-6. PubMed ID: 21402120
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Berk M; Ichim C; Brook S
Int Clin Psychopharmacol; 2001 Mar; 16(2):87-92. PubMed ID: 11236073
[TBL] [Abstract][Full Text] [Related]
9. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.
Cho SJ; Yook K; Kim B; Choi TK; Lee KS; Kim YW; Lee JE; Suh S; Yook KH; Lee SH
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):208-11. PubMed ID: 21095214
[TBL] [Abstract][Full Text] [Related]
10. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study.
Stenberg JH; Terevnikov V; Joffe M; Tiihonen J; Tchoukhine E; Burkin M; Joffe G
Int J Neuropsychopharmacol; 2010 May; 13(4):433-41. PubMed ID: 19941694
[TBL] [Abstract][Full Text] [Related]
11. Add-on mirtazapine improves orgasmic functioning in patients with schizophrenia treated with first-generation antipsychotics.
Terevnikov V; Stenberg JH; Tiihonen J; Burkin M; Joffe G
Nord J Psychiatry; 2017 Jan; 71(1):77-80. PubMed ID: 27701952
[TBL] [Abstract][Full Text] [Related]
12. Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia.
Caforio G; Di Giorgio A; Rampino A; Rizzo M; Romano R; Taurisano P; Fazio L; De Simeis G; Ursini G; Blasi G; Nardini M; Mancini M; Bertolino A
J Clin Psychopharmacol; 2013 Dec; 33(6):810-2. PubMed ID: 24113675
[No Abstract] [Full Text] [Related]
13. Adjunct mirtazapine for negative symptoms of schizophrenia.
Phan SV; Kreys TJ
Pharmacotherapy; 2011 Oct; 31(10):1017-30. PubMed ID: 21950644
[TBL] [Abstract][Full Text] [Related]
14. Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia--a path model investigation.
Stenberg JH; Terevnikov V; Joffe M; Tiihonen J; Chukhin E; Burkin M; Joffe G
Neuropharmacology; 2013 Jan; 64():248-53. PubMed ID: 22750079
[TBL] [Abstract][Full Text] [Related]
15. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.
Koran LM; Gamel NN; Choung HW; Smith EH; Aboujaoude EN
J Clin Psychiatry; 2005 Apr; 66(4):515-20. PubMed ID: 15816795
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia.
Vidal C; Reese C; Fischer BA; Chiapelli J; Himelhoch S
Clin Schizophr Relat Psychoses; 2015; 9(2):88-95. PubMed ID: 23491969
[TBL] [Abstract][Full Text] [Related]
17. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial.
Poyurovsky M; Pashinian A; Weizman R; Fuchs C; Weizman A
Biol Psychiatry; 2006 Jun; 59(11):1071-7. PubMed ID: 16497273
[TBL] [Abstract][Full Text] [Related]
18. A case of pulmonary thromboembolism and rhabdomyolysis during therapy with mirtazapine and risperidone.
Zink M; Knopf U; Argiriou S; Kuwilsky A
J Clin Psychiatry; 2006 May; 67(5):835. PubMed ID: 16841636
[No Abstract] [Full Text] [Related]
19. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study.
Zoccali R; Muscatello MR; Cedro C; Neri P; La Torre D; Spina E; Di Rosa AE; Meduri M
Int Clin Psychopharmacol; 2004 Mar; 19(2):71-6. PubMed ID: 15076014
[TBL] [Abstract][Full Text] [Related]
20. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder.
Smith WT; Glaudin V; Panagides J; Gilvary E
Psychopharmacol Bull; 1990; 26(2):191-6. PubMed ID: 2236455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
